Aquestive Therapeutics Inc (AQST) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aquestive Therapeutics Inc (AQST) has a cash flow conversion efficiency ratio of 0.252x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.47 Million) by net assets ($-33.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aquestive Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Aquestive Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Aquestive Therapeutics Inc for a breakdown of total debt and financial obligations.
Aquestive Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aquestive Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tianjin Yiyi Hygiene Products Co Ltd
SHE:001206
|
0.043x |
|
Shandong Longji Machinery Co Ltd
SHE:002363
|
0.053x |
|
Hangzhou Wensli Silk Culture Co. Ltd.
SHE:301066
|
N/A |
|
OPTHEA LTD (SP.ADR/8)
F:UKJ2
|
N/A |
|
Krispy Kreme Inc
NASDAQ:DNUT
|
0.061x |
|
Insteel Industries Inc
NYSE:IIIN
|
-0.002x |
|
Consolidated Water Co Ltd
NASDAQ:CWCO
|
0.068x |
|
Canada Goose Holdings Inc
TO:GOOS
|
0.579x |
Annual Cash Flow Conversion Efficiency for Aquestive Therapeutics Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Aquestive Therapeutics Inc from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see AQST market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-33.66 Million | $-52.43 Million | 1.558x | +162.03% |
| 2024-12-31 | $-60.16 Million | $-35.76 Million | 0.594x | +892.16% |
| 2023-12-31 | $-106.49 Million | $-6.38 Million | 0.060x | -27.44% |
| 2022-12-31 | $-118.55 Million | $-9.79 Million | 0.083x | -79.44% |
| 2021-12-31 | $-82.13 Million | $-32.98 Million | 0.402x | -57.16% |
| 2020-12-31 | $-48.50 Million | $-45.46 Million | 0.937x | -90.47% |
| 2019-12-31 | $-6.12 Million | $-60.21 Million | 9.835x | +863.12% |
| 2018-12-31 | $10.08 Million | $-12.99 Million | -1.289x | -486.31% |
| 2017-12-31 | $-26.50 Million | $5.82 Million | -0.220x | -147.26% |
| 2016-12-31 | $-17.58 Million | $-8.18 Million | 0.465x | +226.96% |
| 2006-12-31 | $25.26 Million | $-9.26 Million | -0.366x | +73.28% |
| 2005-12-31 | $4.67 Million | $-6.39 Million | -1.371x | -- |
About Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulati… Read more